Prevention of Seasonal Affective Disorder

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Seasonal Affective Disorder (SAD)

Treatments: Drug: Investigational Seasonal Affective Disorder (SAD) Drug

Study type: Interventional

Funder types: Industry

Identifiers

NCT00046449

398149

Details and patient eligibility

About

A Placebo Controlled Study Evaluating The Effectivess Of Medication In Preventing Seasonal Affective Disorder

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: (Patient must meet these criteria in order to be eligible for this study.)

• Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern.

Exclusion Criteria: (Patient cannot meet these criteria in order to be eligible for this study.)

• Patient has a current or past history of seizure disorder or brain injury.
• Patient has a history or current diagnosis of anorexia nervousa or bulimia.
• Patient has recurrent summer depression more frequently than winter depression.
• Patient has primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders.
• Patient has initiated psychotherapy within the last 3 months.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind